Cite This Page

Citation styles for Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients

APA style

Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients. (2024, January 28). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 22:28, May 1, 2024 from https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247.

MLA style

"Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 28 Jan 2024, 09:56 UTC. 1 May 2024, 22:28 <https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 28 January 2024, 09:56 UTC, <https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247> [accessed 1 May 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247 (accessed May 1, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 28, 09:56 UTC [cited 2024 May 1]. Available from: https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247.

Bluebook style

Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients, https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247 (last visited May 1, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247",
   note = "[Online; accessed 1-May-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred:

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Is a result of worldwide phase Three or more studies regarding ravulizumab ALXN1210 as opposed to eculizumab in adults together with paroxysmal nocturnal hemoglobinuria subgroup examination associated with Japanese patients --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Is_a_result_of_worldwide_phase_Three_or_more_studies_regarding_ravulizumab_ALXN1210_as_opposed_to_eculizumab_in_adults_together_with_paroxysmal_nocturnal_hemoglobinuria_subgroup_examination_associated_with_Japanese_patients&oldid=623247}",
   note = "[Online; accessed 1-May-2024]"
 }